IVXpress, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
IVXpress, Inc. - overview
Established
2013
Location
Brentwood, TN, US
Primary Industry
Biotechnology
About
Based in Tennessee, US, and founded in 2013 by Doug Ghertner, IVXpress, Inc. , provides biologic injections and infusions for patients with chronic conditions. The company has approximately 50 infusion centers across 16 markets as of 2021. In September 2021, IVXpress, Inc.
raised series F funding from Great Hill Partners. IVXpress, Inc. works with adult and pediatric patients with chronic conditions such as multiple sclerosis, Crohn’s disease, rheumatoid arthritis, osteoporosis, pediatric and adult immunotherapy, vitamin and mineral deficiencies, and immune system disorders to provide hospital-based infusion and injection therapy through local centers. As part of the 2021 funding, IVXpress, Inc.
will accelerate its entry into new markets in 2022 and realize its vision of becoming the preferred destination for pharmaceutical care for patients with complex chronic conditions.
Current Investors
McKesson Ventures, Health Velocity Capital, Nueterra Capital Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Chiropractic, Orthopedic & Physical Therapy
Website
www.ivxhealth.com
Company Stage
Series F
Total Amount Raised
Subscriber access only
IVXpress, Inc. - employee data
IVXpress, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer & Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.